The objective of this study was to describe characteristics at diagnosis and outcomes of adults with soft tissue sarcoma. METHODS: The authors conducted a retrospective multicenter study of 12,262 patients who were treated between January 1980 and 31 December 2013 in French Sarcoma Group centers and enrolled in the "Conticabase." Diagnoses were systematically reviewed by expert pathologists, and entities were classified according to the 2013 World Health Organization classification. Diagnostic characteristics, treatments, and outcomes are described for the entire cohort, for the subgroup of patients with translocationrelated sarcomas, and for 9 different histologic subtypes. RESULTS: The results stressed the magnitude of heterogeneity among adult sarcomas. For example, compared with other sarcomas, translocation-related sarcomas (2143 tumors; 20.8%) were associated with a younger age at presentation (40.6 vs 60.0 years; P <.0001), a low rate of predisposing conditions (0.01% vs 22.3%; P <.0001), a higher rate of lymph node involvement (4.7% vs 1.3%; P <.0001), and a higher rate of synchronous metastasis (11.9% vs 6.7%; P <.001); and complete (R0) resection (41.6% vs 31.9%; P <.0001), receipt of (neo)adjuvant radiation therapy (62.6% vs 42.2%; P <.0001), and receipt of (neo)adjuvant chemotherapy (36.6% vs 22.3%; P <.0001) were significantly more frequent. Overall, translocation-related sarcomas were associated with a lower rate of local relapse (18.1% vs 26.0%; P <.0001) but a higher rate of metastatic relapse (42.0% vs 30.7%; P <.0001). CONCLUSIONS: Collaborative efforts are urgently needed to better assess the natural history and management options for every histologic subtype of sarcoma.
INTRODUCTION
The natural history and outcome of localized soft tissue sarcomas widely varies by both intrinsic (histologic subtypes, size, grade, lymph node involvement, etc) 1,2 and extrinsic (initial diagnosis modalities, quality of initial surgery, expertise of the multidisciplinary team in charge of the patient, etc) prognostic factors. [3] [4] [5] In particular, several studies have highlighted the major importance of a second pathologic opinion to confirm the initial diagnosis. [4] [5] [6] [7] However, large multicenter studies providing an overview with clinicopathologic descriptions and analyses of outcomes are rare. Therefore, estimating the distribution of prognostic factors or outcomes is imprecise for different molecular and clinical subsets of sarcomas.
In France, 3 successive cancer plans have provided support and resources to better manage rare cancers, particularly adult sarcomas, which represent approximately 2% of all adult cancers. One of the first objectives was to improve the accuracy of pathologic diagnosis using a network of expert pathologists in charge of systematic second opinions in cases of suspected sarcomas. These expert pathologists are trained on a regular basis concerning the most recent immunohistochemistry and molecular biology methods available. Since 1980, this group of expert pathologists has systematically entered all newly diagnosed patients managed by reference centers into a shared database, namely, the ConticaBase, which is supported and funded by the Sixth Framework Program (FP6). The FP6 (Contianet) provides structural support and international access to initial national tools (available at conticabase.org; accessed July 11, 2016) . The ConticaBase database includes data from patients who received treatment at reference centers before initial treatment. The objective of the database was to gather a large data set of actual patients who had soft tissue sarcomas centrally confirmed by expert pathologists along with documented follow-up. It is an annotated virtual tumor bank that includes 16,328 incident cases. Subsequently, the French National Cancer Institute (INCa) has labeled different networks of expertise at the national level, including: RRePS (responsible for rendering a free-of-charge and systematic second opinion by an expert pathologist for patients with suspected sarcoma), NetSarc (a network of multidisciplinary centers dedicated to soft tissue sarcoma management), and ReSOS (a network in charge of managing adult bone sarcomas).
Patients who received treatment at dedicated clinical multidisciplinary centers between January 1, 1980 and December 31, 2013 were enrolled in the ConticaBase. At a median follow-up of 4.9 years, this large database describes the natural history of confirmed soft tissue sarcomas with prospective follow-up. Here, we report the first analysis of this database to describe the clinicopathologic presentation, distribution of prognostic factors, and outcome of all histologic subtypes, including rare entities, to provide a benchmark for better decision making in everyday practice and elaborate on future studies and strategies to improve patient outcomes.
MATERIALS AND METHODS

Central Diagnosis by a Group of Reference Sarcoma Pathologists
Every diagnosis was confirmed by at least 1 of the pathologist experts in the network. Moreover, a collegial third reading for potentially difficult cases has been routinely performed since 1982 in monthly meetings of the French Sarcoma Group (FSG) pathologists. Between 2009 and 2015, every innovative diagnostic method using immunohistochemistry or molecular biology tests was systematically applied, and every suspected case was systematically reviewed and reclassified, where applicable. Therefore, the current database includes a prospective, multicenter series of confirmed cases with immunohistochemistry and molecular analyses as supporting diagnostic methods. The cases were classified in compliance with the fourth edition of the World Health Organization Classification of Soft Tissue Tumours. 8 The histologic subtypes were classified as follows: atypical lipomatous tumor (ALT/LPS), adult-type rhabdomyosarcoma (RMS), alveolar RMS, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, dedifferentiated liposarcoma (LPS), desmoid-type fibromatosis, desmoplastic round cell tumor, embryonal RMS, epithelioid hemangioendothelioma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, extraskeletal osteosarcoma, intimal sarcoma, low-grade fibromyxoid sarcoma leiomyosarcoma, malignant peripheral nerve sheath tumor, malignant solitary fibrous tumor, myxofibrosarcoma, myxoid LPS, peripheral neuroectodermal tumor (PNET) (Ewing sarcoma), pleomorphic LPS, round cell LPS, sclerosing epithelioid fibrosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, undifferentiated sarcoma, and well differentiated LPS. In the current analysis, ALT/LPS (arising in limbs or the superficial trunk) and well differentiated LPS (localized in the internal trunk) were classified into 1 subtype (WD-LPS). According to current recommendations, grade is not applicable to the following translocation-related sarcomas: alveolar RMS, alveolar soft-part sarcoma, clear cell sarcoma, desmoplastic round cell tumor, epithelioid hemangioendothelioma, extraskeletal myxoid chondrosarcoma, lowgrade fibromyxoid sarcoma, myxoid LPS, round cell LPS, and sclerosing epithelioid fibrosarcoma.
Eligibility
All consecutive cases treated in total or in part at 1 of the 22 reference centers between January 1, 1980 and December 31, 2013 were included in this study. Gastrointestinal stromal tumors were not included.
Description of Collected Parameters
We systematically collected: 1) tumor characteristics (histologic subtypes, molecular biology tests, primary location, depth, lymph node involvement or metastasis at Several procedures on data have been set up, including procedures for detecting potential duplicate patients and missing data, controlling data coherence, and histologically reviewing tumors. Currently, data management is designed according to 3 levels, and the following documents and procedures have been established: 1) database structure (data dictionary, structured data, traceability of all modifications of recorded data, and contextual help), 2) data circuit organization (identification and qualification of contributors and training of participants) and 3) quality data management (systematic and periodical duplicate search and periodical update of new samples and evolution of patients).
Statistical Analysis
The objectives of the current analysis were to describe: 1) the characteristics and outcomes of all patients with sarcoma; 2) the characteristics and outcomes of all translocation-related sarcomas, including rare subtypes; and 3) the characteristics and outcomes of the 10 most common histologic subtypes. We used classical methods to describe the study population: number of patients, percentages of categorical data, and means and standard deviations for continuous data. Continuous parameters were compared using the Student t test. Odd ratios and their 95% confidence intervals were calculated for every subtype of adult soft tissue sarcoma.
Survival analyses were conducted in compliance with Definitions for the Assessment of Time-to-Event Endpoints in Cancer Trials (DATECAN) recommendations. 9 Overall survival (OS) was calculated from the date of diagnosis date to the date of death, regardless of cause, or the date of last-follow-up (censored data). Local relapse-free survival (LRFS) was calculated from the date of diagnosis to the date of either local relapse or last follow-up/death (censored data). Metastasis relapse-free survival (MRFS) was calculated from the date of diagnosis to the date of metastasis diagnosis or the date of death, regardless of cause, or to the date of last follow-up (censored data). Survival curves were drawn using the KaplanMeier method using the SAS statistical software package (version 9.3; SAS Institute, Cary, NC). Finally, OS and LRFS were calculated for 10,197 patients, and MRFS was calculated for 10,192 patients.
RESULTS
Overview of the 10,262 Patients
The study population included of 5331 women (51.9%) and 4931 men (48.1%), with a mean 6 standard deviation age of 53.0 6 18.9 years. Some pre-existing conditions were observed: a prior history of cancer (n 5 1123; 10.9%), receipt of prior radiation therapy (n 5 563; 5.5%), pre-existing lymphedema (n 5 68; 0.7%), LiFraumeni syndrome (n 5 7; 0.1%), peripheral neurofibromatosis (n 5 127; 1.2%), familial adenomatous polyposis (n 5 25; 0.2%), or other pre-existing genetic conditions (3 cases only). Overall, human immunodeficiency virus infection was exceptional in this series (1 case only). The most common primary sites were: limb (n 5 4808; 46.9%); internal trunk, including retroperitoneal sarcoma (n 5 2092; 20.4%), trunk wall (n 5 2089; 20.3%), and head and neck (n 5 534; 5.2%). The clear majority of adult soft tissue sarcomas were deep-seated (n 5 8895; 86.7%). The distribution according of histologic subtypes is provided in Table 1 . Tumor grade was assigned as follows: grade 1 (n 5 1585; 15.4%), grade 2 (n 5 3121; 30.4%), grade 3 (n 5 3938; 38.4%), and not available or assessable (n 5 1618; 15.7%). The mean 6 standard deviation tumor size was 106.3 6 77.3 mm. Lymph node involvement at diagnosis was rare (n 5 213; 2.1% size percentage), and metastasis was present in 804 cases (7.8%).
Some patients underwent previous surgery outside the reference center (n 5 4751; 46.3%) and subsequently underwent re-operation at the reference center (n 5 1354; 13.2%). Overall, 9009 patients (87.8%) underwent surgery, including 315 amputations (3.5% of surgical patients). The quality of surgery in 6683 patients was documented as complete resection (R0) (n 5 3882; 58.1%), resection with microscopic residual tumor (R1) (n 5 2431; 36.3%), and resection with macroscopic residual tumor (R2) (n 5 370; 5.5%). Adjuvant and neoadjuvant radiation therapy were received by 4432 (36.1%) and 341 (2,8%) patients, respectively; and neoadjuvant and adjuvant chemotherapy were received by 1161 (11.3%) and 1440 (14.0%) patients, respectively. At the end of initial management, 7462 patients (72.7%) achieved local control.
The median follow-up was 4.9 years (95% confidence interval, 4.7-5.0). Table 1 summarizes the outcome according to histologic subtype. Five-year OS differed widely per histologic subtype: The 2 subtypes associated with better OS were desmoid tumor (5-year OS, 97.3%) and atypical lipomatous tumor (5-year OS, 95.4%), whereas the 2 histologic subtypes associated with the worst OS were desmoplastic round cell tumor (5-year OS, 11.0%) and alveolar RMS (5-year OS, 25.6%). Five-year LRFS also differed widely according to histologic subtype: The 2 subtypes associated with better LRFS were low-grade fibromyxoid sarcoma (5-year LRFS, 80.3%) and atypical lipomatous tumor (5-year LRFS, 79.1%), whereas the 2 subtypes associated with the worst LRFS were desmoplastic round cell tumor (5-year LRFS, 11.4%) and alveolar RMS (5-year LRFS, 20.1%). Excluding subtypes that were unable to metastasize (desmoid tumor and WD-LPS), the 2 subtypes associated with better 5-year LRFS were well differentiated LPS (5-year LRFS, 84.8%) and low-grade fibromyxoid sarcoma (5-year LRFS, 83.6%), and the histologic subtypes associated with the worst 5-year LRFS were desmoplastic round cell tumor (5-year LRFS, 5.8%) and alveolar RMS (5-year LRFS, 25.3%).
Translocation-Related Sarcomas
Histologic subtypes could be classified within 3 major groups: sarcomas with complex genomic alterations (n 5 4406; 42.9%), tumors associated with mouse double-minute 2 homolog (MDM2) amplification (n 5 1827; 17.8%), and translocation-related sarcomas (n 5 2143; 20.8%). In this study, descriptive analyses were focused on translocation-related sarcomas. This group included 13 histologic subtypes: synovial sarcoma (n 5 760; 7.4%), myxoid LPS (n 5 436; 4.2%), soft tissue and visceral PNET (n 5 205; 2.0%), round cell LPS (n 5 183; 1.8%), alveolar RMS (n 5 122; 1.2%), malignant solitary fibrous tumor (n 5 86; 0.8%), clear cell sarcoma (n 5 63; 0.6%), low-grade fibromyxoid sarcoma (n 5 60; 0.6%), desmoplastic round cell tumor (n 5 56; 0.5%), extraskeletal myxoid chondrosarcoma (n 5 54; 0.5%), alveolar soft-part sarcoma (n 5 48; 0.5%), epithelioid hemangioendothelioma (n 5 42; 0.4%), and sclerosing epithelioid fibrosarcoma (n 5 28; 0.3%). Compared with patients who had other sarcomas, the median age of those who had translocation-related sarcomas was younger (40.6 vs 60.0 years; P < .0001) (Fig. 1 ), but the median tumor size was similar (80 mm for both; P 5 .9071). In addition, compared with patients who had other sarcoma types, those with translocation-related sarcoma displayed completely different characteristics (Table  2 ). There was a significantly low rate of the following preexisting conditions: prior history of cancer, prior history of radiotherapy, pre-existing lymphedema, and peripheral neurofibromatosis (0.01% vs 22.2%; P < .0001). Translocation-related sarcomas were more frequently localized in the limbs (60.7% vs 43.2%; P < .0001) and the head and neck (12.7% vs 4.9%; P < .0001). Grade 3 sarcomas were significantly less frequent (31.6% vs 40.1%; P 5 .0021), and translocation-related sarcomas more frequently included deep tumors (93.3% vs 84.9%; P < .0001). Lymph node involvement was 3 times more frequent in translocation-related sarcoma compared with other sarcomas (4.7% vs 1.3%; P < .0001), as was metastasis at diagnosis (11.9% vs 6.7%; P < .0001). Surgery (89.4% vs 87.3%; P < .0001) and initial surgery outside the reference network (49.7% vs 45.3%; P < .0001) were more frequent among patients with translocation-related sarcoma, as were R0 resection (41.6% vs 31.9%; P < .0001), receipt of (neo)adjuvant radiation therapy (33.6% vs 33.3%; P < .0001), and receipt of (neo)adjuvant chemotherapy (36.6% vs 22.3; P < .0001). After initial management, local control was more frequently obtained among patients who had translocation-related sarcomas, and their rate of local relapse was lower compared with that among patients who had other types of sarcoma (18.1% vs 26.0%; P < .0001); however, those with translocation-related sarcomas more frequently Outcome of 29 Sarcoma Subtypes/Penel et al developed metastatic relapse (42.0% vs 30.7%; P < .0001).
Characteristics and Outcomes of the 10 Most Common Histologic Subtypes
The information in Table 3 and in the Supporting Tables  1 through 11 (see online supporting information) describes the main characteristics associated with the 10 most common histologic subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma, undifferentiated sarcoma, WD-LPS, dedifferentiated liposarcoma, synovial sarcoma, desmoid tumor, myxofibrosarcoma, myxoid liposarcoma, and angiosarcoma. Table 3 indicates that most of the factors were different across the histologic subtypes. Supporting Figures 1 through 10 depict the OS, LRFS, and MRFS of patients who had these 10 histologic subtypes (see online supporting information).
DISCUSSION
The large database constructed in the current study describes the distribution of the main characteristics and outcomes of 10,262 adult patients with sarcomas. The current results indicate that initial characteristics and outcomes differ widely across the different histologic subtypes. This database offers major advantages, including high-quality clinical and pathologic data, central pathologic review and continuous diagnostic update, systematic use of molecular biology tools for confirming diagnoses, a multicenter nature, and relatively long-term follow-up. This tool provides a benchmark historical control for future clinical trials that test novel strategies. Nevertheless, the current database had several limitations, including potential selection bias (because all patients were at least partly managed in reference centers), and the current database is not exhaustive compared with registries. We previously reported differences in the management of desmoid tumors inside and outside of the reference center network. 6 We have also observed that the management of sarcoma differed widely between the different reference centers (eg, indications for and modalities of neoadjuvant treatment). Nevertheless, several studies have clearly demonstrated that compliance to guidelines was better inside the reference center network compared with other hospitals, particularly in terms of initial diagnosis management. 10, 11 Furthermore, several studies have reported a better quality of curative-intent surgery in reference centers (R0 resection rates). 10, 12, 13 However, a large nationwide survey will be necessary to appropriately measure the disparities inside and outside the reference center network. The current analysis does not reflect the real-life management and outcome of adult patients with soft tissue sarcoma in France, although it does depict the management and outcome of such patients in reference centers. Furthermore, some could believe the median follow-up was relatively short despite the duration of the study.
The current analysis indicates that initial characteristics and outcomes differ widely according to histologic subtypes or molecular subgroups (complex genomic alterations vs MDM2 amplification vs specific, translocationrelated sarcomas), suggesting that the collection of all histologic subtypes when studying locoregional treatment is not relevant and is intrinsically misleading if the histologic subtypes vary significantly across these median-sized series. Characteristics and outcomes must be analyzed based on histologic subtypes. Further analyses will be required regarding rare histologic subtypes and will require international collaborative efforts.
Adult soft tissue sarcoma cannot be regarded as a single disease composed of various diseases with completely different natural histories. Therefore, future clinical research requires focusing on each histologic subtype to improve knowledge and better individualize management. Individualizing local treatment according to each histologic subtype will require a dedicated retrospective database, a prospective collaborative database, and most likely histology-driven clinical trials. The role and impact of (neo)adjuvant treatment should be assessed for each histologic subtype. However, results from the first randomized trial assessing histology-tailored neoadjuvant compared with epirubicin-ifosfamide do not support this hypothesis.
14 For patients with advanced sarcoma, the results from recently conducted clinical trials clearly demonstrate the importance of stratification according to histologic subtype and of conducting trials dedicated to histologic subtypes (eg, the role of trabectedin in liposarcoma or leiomyosarcoma 15 or characterizing the role of eribulin in liposarcoma 16 and of weekly paclitaxel in angiosarcoma 17 . Our current results could provide a useful benchmark for future research.
The main limitation of this study was the enrollment duration (from 1980 to 2013). However, to our knowledge, it is the largest published series, and the median follow-up was 4.9 years. Also, because of the rarity of some histologic subtypes, this long-term recruitment period was necessary.
In conclusion, the current results demonstrate the importance of considering the histologic subtype when studying adult soft tissue sarcoma at the local stage. The
Original Article current study is based on a biased database describing the outcomes of patients who were managed at reference centers. The FSG is currently analyzing another nationwide database, which includes all consecutive patients who were treated in France from 2009 to 2015 within and outside of the reference centers network.
